Ayesha Wasim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ayesha Wasim has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Maaz Amir
Department of Medicine, King Edward Medical University, Mayo Hospital, Lahore, Punjab, Pakistan
2 shared publications - Abdul Haseeb Hasan
Kigali Kigali City Oli Health Magazine Organization Kigali
1 shared publication Ahmad Hassan
Department of Medicine, King Edward Medical University, Department of Medicine, Mayo Hospital, Lahore, Punjab, Pakistan
1 shared publication- Ahmad Hassan
King Edward Medical University, Lahore, Punjab
1 shared publication - Ahsan Raza Raja
Department of Medicine, Aga Khan University, Karachi, Pakistan
1 shared publication - Asad Ali Ahmed Cheema
Department of Medicine, International School of Medicine, International University of Kyrgyzstan, Bishkek, Kyrgyzstan
1 shared publication
Latest Publications
- Open Access
- 23 October 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (43) , e51220
Acute kidney injury and 30-day unplanned cirrhosis readmissions
30-day unplanned readmissions after hospitalization for liver cirrhosis are common. Acute kidney injury (AKI) may be associated with higher early readmission risk. Using the Nationwide Readmissions Database 2016 to 2017, we identified adults with an index cirrhosis admission from January through November by International Classification of Diseases Tenth Revision Clinical Modification (ICD-10-CM) codes. AKI was defined by N17.x during the index stay. Unplanned 30-day readmissions were identified after excluding planned readmissions and trauma-related hospitalizations. Survey-weighted multivariable logistic regression adjusted for patient, clinical, and hospital factors. Among 1,68,816 index admissions, AKI occurred in 25.6%. Overall, 25.0% had unplanned 30-day readmission, higher with AKI than without (26.0% vs 24.2%; absolute difference 1.8 percentage points). AKI was independently associated with readmission (adjusted odds ratio 1.10, 95% confidence interval 1.05–1.16). AKI admissions had longer length of stay (median 6 vs 4 days), higher inflation-adjusted charges ($58,507 vs $32,587), and nonhome discharge (34% vs 16%; all P < .001). Readmissions occurred at a median of 12 days and had 7.72% in hospital mortality. Ascites and chronic kidney disease were strong predictors. AKI was associated with readmission among patients without chronic kidney disease but not among those with it (interaction P < .001). AKI during the index admission was associated with unplanned 30-day readmission, although the association was modest in magnitude, and marked a high-risk cirrhosis population with greater resource use. Because of the observational, retrospective design, causality cannot be established.
- 23 October 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (43) , e51220
Open AccessAcute kidney injury and 30-day unplanned cirrhosis readmissions
30-day unplanned readmissions after hospitalization for liver cirrhosis are common. Acute kidney injury (AKI) may be associated with higher early readmission risk. Using the Nationwide Readmissions Database 2016 to 2017, we identified adults with an index cirrhosis admission from January through November by International Classification of Diseases Tenth Revision Clinical Modification (ICD-10-CM) codes. AKI was defined by N17.x during the index stay. Unplanned 30-day readmissions were identified after excluding planned readmissions and trauma-related hospitalizations. Survey-weighted multivariable logistic regression adjusted for patient, clinical, and hospital factors. Among 1,68,816 index admissions, AKI occurred in 25.6%. Overall, 25.0% had unplanned 30-day readmission, higher with AKI than without (26.0% vs 24.2%; absolute difference 1.8 percentage points). AKI was independently associated with readmission (adjusted odds ratio 1.10, 95% confidence interval 1.05–1.16). AKI admissions had longer length of stay (median 6 vs 4 days), higher inflation-adjusted charges ($58,507 vs $32,587), and nonhome discharge (34% vs 16%; all P < .001). Readmissions occurred at a median of 12 days and had 7.72% in hospital mortality. Ascites and chronic kidney disease were strong predictors. AKI was associated with readmission among patients without chronic kidney disease but not among those with it (interaction P < .001). AKI during the index admission was associated with unplanned 30-day readmission, although the association was modest in magnitude, and marked a high-risk cirrhosis population with greater resource use. Because of the observational, retrospective design, causality cannot be established.
- Open Access
- 14 October 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (11) , 7399-7412
Comparative evaluation of IV ketorolac and IV paracetamol in laparoscopic surgeries: a systematic review and meta-analysis
Background: Effective postoperative pain control is essential for enhanced recovery after laparoscopic surgery. Intravenous ketorolac and paracetamol are widely used non-opioid agents in multimodal analgesia, but their relative efficacy and safety remain controversial. Methods: Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines, databases were searched through September 2025 for randomized and comparative studies of intravenous (IV) ketorolac versus IV paracetamol. Pooled effect estimates with 95% confidence intervals were calculated using RevMan 5.4. The primary outcome was postoperative visual analog scale (VAS) pain scores; secondary outcomes included the timing and use of rescue analgesia, hemodynamic parameters, and adverse events. Results: Eight studies encompassing 540 patients met inclusion criteria. IV ketorolac significantly reduced VAS scores at 2 hours (MD = −0.95; 95% CI: −1.17 to −0.74; P < 0.00001), 4 hours (MD = −0.99; 95% CI: −1.62 to −0.35; P = 0.002), and 8 hours (MD = −0.45; 95% CI: −0.78 to −0.13; P = 0.006) postoperatively compared with IV paracetamol. The time to first rescue analgesia was significantly longer with ketorolac (MD = 1.93; 95% CI: 1.26–2.61; P < 0.00001). Postoperative vomiting occurred less frequently with ketorolac, while other adverse events and hemodynamic parameters were comparable between the groups. Substantial statistical heterogeneity was present for some outcomes. Conclusion: Intravenous ketorolac provides better early postoperative analgesia and longer-lasting pain relief than intravenous paracetamol following laparoscopic surgery, without increased adverse events. Vomiting was also less frequent with ketorolac. Both agents showed acceptable short-term safety and may be used for multimodal, opioid-sparing analgesia guided by patient and procedural factors.
- 14 October 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (11) , 7399-7412
Open AccessComparative evaluation of IV ketorolac and IV paracetamol in laparoscopic surgeries: a systematic review and meta-analysis
Background: Effective postoperative pain control is essential for enhanced recovery after laparoscopic surgery. Intravenous ketorolac and paracetamol are widely used non-opioid agents in multimodal analgesia, but their relative efficacy and safety remain controversial. Methods: Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines, databases were searched through September 2025 for randomized and comparative studies of intravenous (IV) ketorolac versus IV paracetamol. Pooled effect estimates with 95% confidence intervals were calculated using RevMan 5.4. The primary outcome was postoperative visual analog scale (VAS) pain scores; secondary outcomes included the timing and use of rescue analgesia, hemodynamic parameters, and adverse events. Results: Eight studies encompassing 540 patients met inclusion criteria. IV ketorolac significantly reduced VAS scores at 2 hours (MD = −0.95; 95% CI: −1.17 to −0.74; P < 0.00001), 4 hours (MD = −0.99; 95% CI: −1.62 to −0.35; P = 0.002), and 8 hours (MD = −0.45; 95% CI: −0.78 to −0.13; P = 0.006) postoperatively compared with IV paracetamol. The time to first rescue analgesia was significantly longer with ketorolac (MD = 1.93; 95% CI: 1.26–2.61; P < 0.00001). Postoperative vomiting occurred less frequently with ketorolac, while other adverse events and hemodynamic parameters were comparable between the groups. Substantial statistical heterogeneity was present for some outcomes. Conclusion: Intravenous ketorolac provides better early postoperative analgesia and longer-lasting pain relief than intravenous paracetamol following laparoscopic surgery, without increased adverse events. Vomiting was also less frequent with ketorolac. Both agents showed acceptable short-term safety and may be used for multimodal, opioid-sparing analgesia guided by patient and procedural factors.
- Open Access
- 7 August 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (32) , e50096
Association of oral vancomycin prophylaxis with Clostridium difficile infection in hematopoietic stem cell transplant recipients: A systematic review and meta-analysis
Background: Clostridium difficile infection (CDI) occurs in up to 30% of hematopoietic stem cell transplant (HSCT) recipients and remains a significant cause of infectious diarrhea. This meta-analysis evaluated the association of oral vancomycin prophylaxis (OVP) with CDI prevention after HSCT. Methods: We conducted a literature search of PubMed, Cochrane, and Google Scholar for articles from inception to July 2025 that compared the safety and efficacy of OVP for CDI in post-HSCT patients. Statistical analysis of the extracted data was conducted using Review Manager 5.4. The odds ratio for dichotomous variables and the mean difference for continuous variables were analyzed along with the corresponding 95% confidence intervals. A random-effects model was applied when heterogeneity was high ( I 2 ≥ 50%), and a fixed-effect model was applied when heterogeneity was low ( I 2 ≤ 50%). Results: This meta-analysis included 5 studies comprising 957 patients, with 490 (51.2%) receiving OVP and 467 (48.8%) not receiving OVP (no OVP). OVP was significantly associated with a reduced incidence of CDI during hospitalization ( P < .00001). Although a lower overall incidence of CDI (hospitalization plus 180-day follow-up) was observed in the OVP group, the result was not statistically significant ( P = .06). A leave-one-out analysis was performed to establish a significant association ( P = .04). In the OVP group, higher rates of grade 2 to 4 acute graft-versus-host disease ( P = .13) and lower rates of bloodstream infections ( P = .74), 1-year event-free survival ( P = .44), and longer hospital stays ( P = .36) were observed, although none reached statistical significance. Conclusion: We conclude that oral vancomycin might be associated with a lower incidence of CDI during hospitalization in post-HSCT recipients and can be considered for CDI prophylaxis. No statistically significant adverse outcomes were observed in the OVP group compared with placebo. However, given the observational nature of these studies, these findings should be considered preliminary. Large-scale randomized controlled trials are needed to confirm the true efficacy and safety profile of OVP in post-HSCT recipients.
- 7 August 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (32) , e50096
Open AccessAssociation of oral vancomycin prophylaxis with Clostridium difficile infection in hematopoietic stem cell transplant recipients: A systematic review and meta-analysis
Background: Clostridium difficile infection (CDI) occurs in up to 30% of hematopoietic stem cell transplant (HSCT) recipients and remains a significant cause of infectious diarrhea. This meta-analysis evaluated the association of oral vancomycin prophylaxis (OVP) with CDI prevention after HSCT. Methods: We conducted a literature search of PubMed, Cochrane, and Google Scholar for articles from inception to July 2025 that compared the safety and efficacy of OVP for CDI in post-HSCT patients. Statistical analysis of the extracted data was conducted using Review Manager 5.4. The odds ratio for dichotomous variables and the mean difference for continuous variables were analyzed along with the corresponding 95% confidence intervals. A random-effects model was applied when heterogeneity was high ( I 2 ≥ 50%), and a fixed-effect model was applied when heterogeneity was low ( I 2 ≤ 50%). Results: This meta-analysis included 5 studies comprising 957 patients, with 490 (51.2%) receiving OVP and 467 (48.8%) not receiving OVP (no OVP). OVP was significantly associated with a reduced incidence of CDI during hospitalization ( P < .00001). Although a lower overall incidence of CDI (hospitalization plus 180-day follow-up) was observed in the OVP group, the result was not statistically significant ( P = .06). A leave-one-out analysis was performed to establish a significant association ( P = .04). In the OVP group, higher rates of grade 2 to 4 acute graft-versus-host disease ( P = .13) and lower rates of bloodstream infections ( P = .74), 1-year event-free survival ( P = .44), and longer hospital stays ( P = .36) were observed, although none reached statistical significance. Conclusion: We conclude that oral vancomycin might be associated with a lower incidence of CDI during hospitalization in post-HSCT recipients and can be considered for CDI prophylaxis. No statistically significant adverse outcomes were observed in the OVP group compared with placebo. However, given the observational nature of these studies, these findings should be considered preliminary. Large-scale randomized controlled trials are needed to confirm the true efficacy and safety profile of OVP in post-HSCT recipients.